Analysts See India’s Glenmark Patent Suits Signal Of Bold Generics Move (India)
This article was originally published in PharmAsia News
Executive Summary
India's Glenmark Pharmaceuticals appears to be increasing its presence in the generics drug market, as revealed by several patent cases the firm has attracted. Sanofi-Aventis of France and Abbott Laboratories of the U.S. have filed a patent-infringement suit in the U.S. against Glenmark's development of a generic to Tarka (trandolapril; verapamil hydrochloride) for treating hypertension. It was only the second patent suit Glenmark has been involved in recent years, but the company also has two other generics filings in the United States. Some analysts believe the company is making an assertive expansion in the generics business. (Click here for more